e-learning
resources
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
New anti-tuberculosis drugs and regimens: 2015 update
D'Ambrosio Lia, Centis Rosella, Sotgiu Giovanni, Pontali Emanuele, Spanevello Antonio, Migliori Giovanni Battista
Source:
ERJ Open Res 2015
Journal Issue:
May
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D'Ambrosio Lia, Centis Rosella, Sotgiu Giovanni, Pontali Emanuele, Spanevello Antonio, Migliori Giovanni Battista. New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Res 2015; 1: 00010-2015
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
New anti-tuberculosis drugs for special populations: a difficult-to-address issue
Source: Eur Respir J 2016; 48: 957-958
Year: 2016
Availability of anti-tuberculosis drugs in Europe
Source: Eur Respir J 2012; 40: 500-503
Year: 2012
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon?
Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Year: 2005
Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance
Source: Eur Respir J 2012; 39: 802-804
Year: 2012
Availability of PCR for second-line drugs in Europe
Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment
Year: 2016
New and repurposed drugs for MDR-TB patients
Source: International Congress 2017 – PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence
Year: 2017
Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy
Source: Eur Respir J 2012; 39: 1263-1266
Year: 2012
Novel drug regimens against MDR-TB
Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis
Year: 2016
Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe
Source: Eur Respir J, 58 (3) 2101196; 10.1183/13993003.01196-2021
Year: 2021
Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study
Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease
Year: 2021
New methodologogic approaches to the management of antituberculous service
Source: Eur Respir J 2003; 22: Suppl. 45, 381s
Year: 2003
Opportunities of application of short regimens for MDR-TBat the expense of using intravenous administration of anti-TB drugs during intensive phase
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey
Source: Eur Respir J 2015; 45: 1081-1088
Year: 2015
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 359s
Year: 2002
New and repurposed TB drugs use in children and adolescents with M/XDR-TB
Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Year: 2017
Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Facts and perspectives in the development of new anti-TB drugs
Source: Annual Congress 2008 - New insights into tuberculosis control
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept